Trader consensus on Polymarket prices an 89% implied probability that CVS Health (CVS) will beat Q1 2026 consensus adjusted EPS estimates of $2.21, reflecting the company's streak of four consecutive quarterly beats with an average surprise of 20.6% and reaffirmed full-year 2026 adjusted EPS guidance of $7.00–$7.20 amid at least $400 billion in revenue. Recent catalysts include a Centers for Medicare & Medicaid Services final rule boosting Medicare Advantage payments by 2.5%—versus a proposed 0.09%—delivering an estimated $13 billion industry reprieve that bolsters Aetna margins after shares rallied from the low $70s. Consensus estimates declined 1.38% over the past 30 days, lowering the bar further, while Health Services segment strength is expected to lead performance ahead of the May 6 earnings release.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
NUEVO
6 may 2026
NUEVO
NUEVO
6 may 2026
As of market creation, CVS Health is estimated to release earnings on May 6, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $2.21 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $2.21 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Trader consensus on Polymarket prices an 89% implied probability that CVS Health (CVS) will beat Q1 2026 consensus adjusted EPS estimates of $2.21, reflecting the company's streak of four consecutive quarterly beats with an average surprise of 20.6% and reaffirmed full-year 2026 adjusted EPS guidance of $7.00–$7.20 amid at least $400 billion in revenue. Recent catalysts include a Centers for Medicare & Medicaid Services final rule boosting Medicare Advantage payments by 2.5%—versus a proposed 0.09%—delivering an estimated $13 billion industry reprieve that bolsters Aetna margins after shares rallied from the low $70s. Consensus estimates declined 1.38% over the past 30 days, lowering the bar further, while Health Services segment strength is expected to lead performance ahead of the May 6 earnings release.
As of market creation, CVS Health is estimated to release earnings on May 6, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $2.21 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $2.21 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Mercado abierto: Apr 23, 2026, 5:44 PM ET
Volumen
$285Fecha de finalización
6 may 2026Mercado abierto
Apr 23, 2026, 5:44 PM ETFuente de resolución
https://seekingalpha.com/Resolver
0x65070BE91...As of market creation, CVS Health is estimated to release earnings on May 6, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $2.21 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $2.21 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Trader consensus on Polymarket prices an 89% implied probability that CVS Health (CVS) will beat Q1 2026 consensus adjusted EPS estimates of $2.21, reflecting the company's streak of four consecutive quarterly beats with an average surprise of 20.6% and reaffirmed full-year 2026 adjusted EPS guidance of $7.00–$7.20 amid at least $400 billion in revenue. Recent catalysts include a Centers for Medicare & Medicaid Services final rule boosting Medicare Advantage payments by 2.5%—versus a proposed 0.09%—delivering an estimated $13 billion industry reprieve that bolsters Aetna margins after shares rallied from the low $70s. Consensus estimates declined 1.38% over the past 30 days, lowering the bar further, while Health Services segment strength is expected to lead performance ahead of the May 6 earnings release.
As of market creation, CVS Health is estimated to release earnings on May 6, 2026. The Street consensus estimate for CVS Health’s non-GAAP EPS for the relevant quarter is $2.21 as of market creation. This market will resolve to "Yes" if CVS Health reports non-GAAP EPS greater than $2.21 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If CVS Health releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$285Fecha de finalización
6 may 2026Mercado abierto
Apr 23, 2026, 5:44 PM ETFuente de resolución
https://seekingalpha.com/Resolver
0x65070BE91...Trader consensus on Polymarket prices an 89% implied probability that CVS Health (CVS) will beat Q1 2026 consensus adjusted EPS estimates of $2.21, reflecting the company's streak of four consecutive quarterly beats with an average surprise of 20.6% and reaffirmed full-year 2026 adjusted EPS guidance of $7.00–$7.20 amid at least $400 billion in revenue. Recent catalysts include a Centers for Medicare & Medicaid Services final rule boosting Medicare Advantage payments by 2.5%—versus a proposed 0.09%—delivering an estimated $13 billion industry reprieve that bolsters Aetna margins after shares rallied from the low $70s. Consensus estimates declined 1.38% over the past 30 days, lowering the bar further, while Health Services segment strength is expected to lead performance ahead of the May 6 earnings release.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes